NCT04169906

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

A Phase I Study of TS-142 in Non-Elderly Healthy Participants (Repeated Doses) (A Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TS-142 in Non-Elderly Participants)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: Male
• Age: 20 Years – 39 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety, pharmacokinetics, and pharmacodynamics of repeated dosing of TS-142 when administered once daily to healthy Japanese non-elderly participants.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	Placebo	Participants will receive placebo once daily for 7 consective days
DRUG	TS-142, 10 mg	Participants will receive 10 mg of TS-142 once daily for 7 consective days
DRUG	TS-142, 20 mg	Participants will receive 20 mg of TS-142 once daily for 7 consective days
DRUG	TS-142, 30 mg	Participants will receive 30 mg of TS-142 once daily for 7 consective days

Timeline

• Start date: 2016-07-06
• Primary completion: 2016-10-08
• Completion: 2016-10-08
• First posted: 2019-11-20
• Last updated: 2025-02-28

Locations

1 site across 1 country: Japan